Cargando…
CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma
BACKGROUND: Even acknowledging the game-changing results achieved in the treatment of metastatic melanoma with the use of immune checkpoint inhibitors (ICI), a large proportion of patients (40–60%) still fail to respond or relapse due to the development of resistance. Alterations in the expression o...
Autores principales: | Giraudo, Lidia, Cattaneo, Giulia, Gammaitoni, Loretta, Iaia, Ilenia, Donini, Chiara, Massa, Annamaria, Centomo, Maria Laura, Basiricò, Marco, Vigna, Elisa, Pisacane, Alberto, Picciotto, Franco, Berrino, Enrico, Marchiò, Caterina, Merlini, Alessandra, Paruzzo, Luca, Poletto, Stefano, Caravelli, Daniela, Biolato, Andrea Michela, Bortolot, Valentina, Landoni, Elisa, Ventin, Marco, Ferrone, Cristina R., Aglietta, Massimo, Dotti, Gianpietro, Leuci, Valeria, Carnevale-Schianca, Fabrizio, Sangiolo, Dario |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664597/ https://www.ncbi.nlm.nih.gov/pubmed/37993874 http://dx.doi.org/10.1186/s13046-023-02884-x |
Ejemplares similares
-
Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFRA Wild Type GIST
por: Fiorino, Erika, et al.
Publicado: (2022) -
CD44v6 as innovative sarcoma target for CAR-redirected CIK cells
por: Leuci, V., et al.
Publicado: (2018) -
Full chimaeric CAR.CIK from patients engrafted after allogeneic haematopoietic cell transplant: Feasibility, anti‐leukaemic potential and alloreactivity across major human leukocyte antigen barriers
por: Circosta, Paola, et al.
Publicado: (2022) -
Cytokine Induced Killer cells effectively kill chemo-resistant melanoma cancer stem cells
por: Gammaitoni, Loretta, et al.
Publicado: (2015) -
High BRAF variant allele frequencies are associated with distinct pathological features and responsiveness to target therapy in melanoma patients
por: Berrino, E., et al.
Publicado: (2021)